ViewMind Inc.

This short video (3'25") introduces ViewMind Inc.'s cutting-edge technology for brain health assessment and its potential to optimize cognitive function. Even within the normal range, every brain has room for improvement. Much like an iceberg, brain function is influenced by hidden factors below the surface—vascular and metabolic health, exposure to mold and toxins, and lifestyle choices. Explore how our technology can help unlock and maximize your brain’s full potential. #health #healthcare #brainhealth #preventivehealth Mark Hyman, MD

New Study Links Eye Movement Deficits to Disease Progression in Multiple Sclerosis A new study published in Multiple Sclerosis and Related Disorders reveals a significant correlation between eye movement alterations and both physical and cognitive decline in individuals with multiple sclerosis (MS). The research, titled "Eye movement deficits in Multiple Sclerosis: characterizing executive problems as the disease worsens," utilized ViewMind Atlas? to conduct detailed eye movement analysis. Researchers found that this innovative approach offers a reliable, rapid, non-invasive, and objective method for evaluating cognitive and motor impairments in MS patients. The study highlights the potential of eye movement analysis as a valuable tool for monitoring disease progression and informing treatment strategies. ViewMind Inc. remains dedicated to pioneering data-driven solutions for brain health assessment and is committed to supporting research that advances our understanding of cognitive function across a range of neurological conditions. For more information about ViewMind’s technology and research, contact us. Read the full study here: https://lnkd.in/dhu4Tyvb #MultipleSclerosis #Neurology #BrainHealth #DigitalBiomarkers #EyeTracking #ClinicalResearch #Neurodegeneration #HealthcareInnovation

Alzheimer's Drug Discovery Foundation ’s DIAGNOSTICS ACCELERATOR (DXA) Invests $1.4M in ViewMind’s Brain Health Assessment technology, ViewMind Atlas?. We are proud to announce that ViewMind Inc. has received a $1.4M investment from the DxA, reinforcing their commitment to advancing novel biomarkers, including digital health assessments. This partnership highlights ViewMind's innovative use of eye movement and pupillometry data to enable the early detection of neurological conditions and to monitor treatment impacts on brain health. This milestone underscores two fundamental aspects of our technology: ?? ViewMind Atlas? offers non-invasive, scalable, accurate, and repeatable evaluations of cognitive brain health, independent of cultural or educational differences. ?? The technology addresses a critical need for functional brain assessments that are affordable, precise, and accessible. Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF, says, “ViewMind’s assessment based on ocular phenotyping, has the potential to address a critical need for scalable, accurate, non-invasive, and affordable functional brain assessments. The ability to correlate assessment results with structural brain changes, diagnose Alzheimer’s early and monitor the impact of treatment would be very impactful for drug development and patient care”. Mark Edwards, CEO and Co-founder of ViewMind, says, “ViewMind is honored to receive investment and support from ADDF and DxA, along with access to their expert advisory network. Our mission is to establish ViewMind as the world’s most precise solution for functional and cognitive brain assessments—in essence, the first-ever precision brain meter for accurately measuring functional brain health”. #BrainHealth #CognitiveHealth #Alzheimers #DigitalHealth #NeurologicalDisorders #HealthTech #EyeTracking #InnovationInHealthcare #Biomarkers #PrecisionMedicine

ViewMind Inc. would like to thank TRIUM Global Executive MBA for the invitation to, Mark Edwards, ViewMind CEO & Co-founder, to participate on their panel at CES2025. #CES2025 #BRAINHEALTH #AI

Thanks TRIUM Global Executive MBA for inviting me to participate in their CES2025 event and panel. We had an engaging discussion about the defining technology trends of CES2025 and where we are headed over the next decade. It was great to meet and be inspired by fellow panelists Neal Weinstock, Elizabeth Estes and Mitch Keenan. Thanks also to Dennis Sponer, Sean Paavo Krepp and the other members of the TRIUM team and the audience for their questions. #CES2025 #BRAINHEALTH #AI

As the year comes to a close, we want to take a moment to express our gratitude to our partners and supporters. Together, we advanced our mission of transforming brain health through innovative, data-driven solutions. We look forward to continued collaboration in 2025 as we keep pushing the boundaries of cognitive health assessments. Thank you for being part of our journey. Wishing you all a peaceful holiday season and a successful new year. #BrainHealth #HealthInnovation #CognitiveHealth #ThankYou #BusinessGrowth

We are pleased to share that Dr. Danilo Verge, ViewMind Inc.’s Chief Medical Officer, presented to nearly 300 endocrinologists at the Intensive Course Davidson Mestman 2024 in Miami. His presentation, “Oculomotor Alterations and Cognitive Decline in Cardiometabolic Diseases – A New Diagnostic Modality?”, generated significant interest among specialists. ViewMind’s non-invasive technology offers valuable insights that have the potential to also be relevant for endocrinologists. By detecting cognitive changes in cardiometabolic conditions, our solution has the potential to support earlier intervention and personalized care. We appreciate the opportunity to contribute to discussions that drive innovation in brain health diagnostics. #ViewMind #MedicalEducation #CognitiveHealth #Endocrinology #DiagnosticsInnovation Curso Davidson-Mestman Danilo Verge

ViewMind Inc. is proud to announce its participation in the Bio-Hermes-002 study in collaboration with the Global Alzheimer’s Platform Foundation? (GAP). The Bio-Hermes-002 study is a comprehensive observational platform designed to evaluate the effectiveness of various blood-based and digital biomarkers in detecting and diagnosing Alzheimer’s disease, and to demonstrate correlation with gold standard biomarker and neuroimaging brain assessments. "ViewMind is committed to becoming the leading solution for assessing functional brain health, detecting subtle changes associated with disease progression or treatment. Efforts are actively underway to secure this position. In addition, ViewMind has developed a specialized assessment for Alzheimer’s disease. Initial results indicate high sensitivity and specificity to detect asymptomatic stages over 10 years before symptoms and amnestic MCI. This advancement holds the potential to make a significant impact on healthcare. We are excited to participate in the landmark Bio-Hermes-002 study to validate our results,” said Mark Edwards, CEO & Co-founder of ViewMind Inc. #BioHermes002 #AlzheimersResearch #DiversityInResearch #DigitalBiomarkers #ViewMind #Cognitive Global Alzheimer's Platform Foundation

We deeply appreciate the feature by StartUp Health highlighting ViewMind Inc.! At ViewMind, we are committed to advancing non-invasive precision assessment to transform brain health.? ?? If you haven’t already, watch Mark Edwards discuss our mission and technology on StartUp Health TV. Thank you, StartUp Health, for recognizing our efforts to drive innovation and improve global brain health. #ViewMind #BrainHealth #HealthTransformer #InnovationInHealth #StartUpHealth

We are honored to announce that ViewMind Inc. has been named one of the three winners of the Accelerate UK 2024 competition! The competition was intense, with nearly 360 companies applying. Being selected as a winner underscores the global crisis in brain and mental health, highlighting the urgent need for solutions like ViewMind’s, which offers precise, rapid, scalable, and affordable brain health assessments. We are thrilled to be joining the #AccelerateUK program and look forward to the opportunities it will bring. A huge thank you to the Accelerate UK team for this opportunity, and congratulations to all finalists! #Innovation #BrainHealth #Health #Healthcare Embajada Británica en Argentina